Volume 9, Issue 2 (12-2023)
SJNMP 2023, 9(2): 112-122 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagheri S R, Rezaei Z, Mohammadi L, Heidari A, Alimohammadi E. Evaluation of factors associated with survival of patients with glioblastoma multiform: a 10-year retrospective study in Kermanshah. SJNMP 2023; 9 (2) :112-122
URL: http://sjnmp.muk.ac.ir/article-1-571-en.html
URL: http://sjnmp.muk.ac.ir/article-1-571-en.html
1- School of Medicine , Imam Reza Hospital , Kermanshah University of Medical Sciences, Kermanshah, Iran
2- School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- Clinical Research Development Unit, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Department of Aneasthesiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
5- Department of Neurosurgery, School of Medicine, Imam Reza Hospital Kermanshah University of Medical Sciences, Kermanshah, Iran ,hafez125@gmail.com
2- School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- Clinical Research Development Unit, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Department of Aneasthesiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
5- Department of Neurosurgery, School of Medicine, Imam Reza Hospital Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (989 Views)
Background & Aim: Glioblastoma multiform (GBM) is a highly malignant and aggressive primary brain tumor in adults, associated with a poor prognosis and short life expectancy following diagnosis. This 10-year retrospective study aimed to identify factors influencing the survival of patients with GBM in Kermanshah.
Materials & Methods: A retrospective cohort study was conducted, involving patients diagnosed with GBM who underwent surgery at Kermanshah's educational hospitals between 2008 and 2018. Demographic, clinical, and pathological variables were collected using a checklist extracted from patients' medical records. Patients were followed from the time of surgery until death. Data analysis was performed using Stata 14 software, employing the Cox regression model to assess factors influencing patient survival (p<0.05 considered significant).
Results: A total of 153 patients with GBM were diagnosed during the 10-year period. The mean age of the subjects was 56.32 ± 9.22 years, with 60.8% being male. The average overall survival duration was 18.13 ± 6.84 months. Multivariable Cox regression analysis revealed that age, sex, tumor location, size of necrosis, extent of tumor removal during surgery, and reoperation in recurrence were not significant predictors of survival (p>0.05). However, tumor type, tumor pathology, and temozolomide (TMZ) consumption emerged as the most important factors associated with survival in these patients (p<0.05).
Conclusion: This study highlights tumor type, tumor pathology, and TMZ usage as critical factors influencing the survival of patients with GBM. Considering these factors can greatly contribute to the improved management of GBM patients.
Materials & Methods: A retrospective cohort study was conducted, involving patients diagnosed with GBM who underwent surgery at Kermanshah's educational hospitals between 2008 and 2018. Demographic, clinical, and pathological variables were collected using a checklist extracted from patients' medical records. Patients were followed from the time of surgery until death. Data analysis was performed using Stata 14 software, employing the Cox regression model to assess factors influencing patient survival (p<0.05 considered significant).
Results: A total of 153 patients with GBM were diagnosed during the 10-year period. The mean age of the subjects was 56.32 ± 9.22 years, with 60.8% being male. The average overall survival duration was 18.13 ± 6.84 months. Multivariable Cox regression analysis revealed that age, sex, tumor location, size of necrosis, extent of tumor removal during surgery, and reoperation in recurrence were not significant predictors of survival (p>0.05). However, tumor type, tumor pathology, and temozolomide (TMZ) consumption emerged as the most important factors associated with survival in these patients (p<0.05).
Conclusion: This study highlights tumor type, tumor pathology, and TMZ usage as critical factors influencing the survival of patients with GBM. Considering these factors can greatly contribute to the improved management of GBM patients.
Type of Study: Research |
Subject:
Special
Received: 2023/10/8 | Revised: 2023/12/24 | Accepted: 2023/11/28 | Published: 2023/12/1 | ePublished: 2023/12/1
Received: 2023/10/8 | Revised: 2023/12/24 | Accepted: 2023/11/28 | Published: 2023/12/1 | ePublished: 2023/12/1
References
1. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & therapeutics. 2015;152:63-82. [DOI:10.1016/j.pharmthera.2015.05.005]
2. Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SAA, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomedicine & Pharmacotherapy. 2017;92:681-9. [DOI:10.1016/j.biopha.2017.05.125]
3. Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Current medicinal chemistry. 2017; 24(27): 3002-9. [DOI:10.2174/0929867324666170516123206]
4. Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO molecular medicine. 2014;6(11):1359-70. [DOI:10.15252/emmm.201302627]
5. Crespo I, Vital AL, Gonzalez-Tablas M, del Carmen Patino M, Otero A, Lopes MC, et al. Molecular and genomic alterations in glioblastoma multiforme. The American journal of pathology. 2015;185(7):1820-33. [DOI:10.1016/j.ajpath.2015.02.023]
6. Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020;12(5). [DOI:10.7759/cureus.8195]
7. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):3.
8. Huang B, Li X, Li Y, Zhang J, Zong Z, Zhang H. Current immunotherapies for glioblastoma multiforme. Frontiers in immunology. 2021;11:603911. [DOI:10.3389/fimmu.2020.603911]
9. Kanderi T, Gupta V. Glioblastoma multiforme. StatPearls [Internet]: StatPearls Publishing; 2022.
10. Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes & diseases. 2016;3(3):198-210. [DOI:10.1016/j.gendis.2016.04.007]
11. Muir M, Gopakumar S, Traylor J, Lee S, Rao G. Glioblastoma multiforme: novel therapeutic targets. Expert Opinion on Therapeutic Targets. 2020;24(7):605-14. [DOI:10.1080/14728222.2020.1762568]
12. Ozdemir-Kaynak E, Qutub AA, Yesil-Celiktas O. Advances in glioblastoma multiforme treatment: new models for nanoparticle therapy. Frontiers in physiology. 2018;9:170. [DOI:10.3389/fphys.2018.00170]
13. Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacological Research. 2021;171:105780. [DOI:10.1016/j.phrs.2021.105780]
14. Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). Journal of Clinical Neuroscience. 2013; 20(5):670-75. [DOI:10.1016/j.jocn.2012.05.040]
15. Stoyanov GS, Dzhenkov D, Ghenev P, Iliev B, Enchev Y, Tonchev AB. Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. Medical Oncology. 2018;35:1-10. [DOI:10.1007/s12032-018-1083-x]
16. Swartz AM, Li Q-J, Sampson JH. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy. 2014;6(6):679-90. [DOI:10.2217/imt.14.21]
17. Taylor OG, Brzozowski JS, Skelding KA. Glioblastoma multiforme: an overview of emerging therapeutic targets. Frontiers in oncology. 2019;9:963. [DOI:10.3389/fonc.2019.00963]
18. Urbańska K, Sokołowska J, Szmidt M, Sysa P. Glioblastoma multiforme-an overview. Contemporary Oncology/Współczesna Onkologia. 2014;18(5):307-12. [DOI:10.5114/wo.2014.40559]
19. Van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AM, Vandertop WP, et al. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of neuro-oncology. 2017;135:183-92. [DOI:10.1007/s11060-017-2564-z]
20. Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival analysis of glioblastoma multiforme. Asian Pacific journal of cancer prevention: APJCP. 2018;19(9):2613.
21. Awad AW, Karsy M, Sanai N, Spetzler R, Zhang Y, Xu Y, et al. Impact of removed tumor volume and location on patient outcome in glioblastoma. J Neurooncol. 2017; 135(1): 161-71. [DOI:10.1007/s11060-017-2562-1]
22. Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barceló I, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro-oncology. 2013;15(6):797-805. [DOI:10.1093/neuonc/not013]
23. Gately L, Collins A, Murphy M, Dowling A. Age alone is not a predictor for survival in glioblastoma. Journal of neuro-oncology. 2016;129:479-85. [DOI:10.1007/s11060-016-2194-x]
24. Timmermans M, Sonke G, Van de Vijver K, Van der Aa M, Kruitwagen R. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. European journal of cancer. 2018;88:31-7. [DOI:10.1016/j.ejca.2017.10.030]
25. Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, et al. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. Journal of neurology. 2017;264:350-8. [DOI:10.1007/s00415-016-8355-1]
26. Ortega A, Sarmiento JM, Ly D, Nuño M, Mukherjee D, Black KL, et al. Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. J Clin Neurosci. 2016;24: 105-11. [DOI:10.1016/j.jocn.2015.05.047]
27. Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, et al. Intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO): an open-label, dose-escalation phase I/II trial. Neurosurgery. 2019;84(1):41-9. [DOI:10.1093/neuros/nyy018]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
